Investor Relations

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Our development efforts are directed to advancing the movement of multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Details >>

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.33
Change (%) Stock is Down 0.03 (0.89%)
Volume8,962
Market Cap$208,008,450
Shares Outstanding62,465,000
Data as of 03/12/10 10:29 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
DateTitle 
03/10/10Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral SclerosisPrinter Friendly Version
02/23/10Cytokinetics Announces Non-Clinical Data From Multiple Programs Presented at the Biophysical Society 54th Annual MeetingPrinter Friendly Version
02/12/10Cytokinetics Announces Non-Clinical Data From Multiple Programs to Be Presented at the Biophysical Society 54th Annual MeetingPrinter Friendly Version
02/03/10Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2009 Financial ResultsPrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
There are currently no items available.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Print PagePrint Page  |    Email PageEmail Page  |   Email AlertsEmail Alerts  |   IR ContactsIR Contacts